OP0070 ONSET TO DIAGNOSIS TIME PREDICTS SURVIVAL RATE IN TAKAYASU ARTERITIS
Takayasu arteritis (TA) is large vessel vasculitis. In spite of relatively high 5 to 15 years survival rate, TA affects young persons and causes major cardiovascular events, disability and preterm deaths [1]. Nowadays, though new high-resolution visualization and effective treatment options are avai...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases Jg. 80; S. 37 - 38 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Elsevier B.V
01.06.2021
|
| ISSN: | 0003-4967 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Takayasu arteritis (TA) is large vessel vasculitis. In spite of relatively high 5 to 15 years survival rate, TA affects young persons and causes major cardiovascular events, disability and preterm deaths [1]. Nowadays, though new high-resolution visualization and effective treatment options are available, quite a large number of TA patients remain undiagnosed and untreated for years [2].
To assess the influence of timely TA diagnosis and treatment initiation on the survival rate and cardiovascular events risk.
A retrospective cohort study included 183 patients (139 females, 44 males), enrolled during the period from 1979 to 2018 after TA diagnosis verification according to ACR1990 criteria [3]. All subjects have been followed up at the Sverdlovsk Regional Clinical Hospital 1. Cox regression model was used to compare survival rate.
By enrollment, females median age was 35 [25%-75%: 24 - 44] and in males median age was 34 [26 -42]. Median time duration from the first symptoms onset to the diagnosis verification was 3 [1-7] years in females and [1.5 - 8] years in males. The most common affected arteries were subclavian (55%), carotid (53%), and renal (42%). 5-year survival rate was 92%; 10-year survival rate was 90%; 15-year survival rate was 80%. The median term of survival was 34 [20 - 41] years. 31 deaths (18 males and 13 females) occurred during the follow-up period. Median age of death was 36 [32-44] in females, and 50 [40-57]) in males. The average disease course duration at the time of death was 9.25 years, median term being 6.5 [3-16] in females and 5 [3-10] in males. Also a total of 72 cardiovascular events were recorded during the follow-up period: 27 in men and 45 in women. The median duration of AT course by the development of the first ever event was 10 (5 -20). There were 24 cases of ischemic stroke, 3 transient ischemic attacks, 4 cases of hemorrhagic stroke. Median age of the first ever event was 38 (30 - 49.5). Time duration 4 years or more from AT symptoms onset to diagnosis was associated with significantly more frequent cardiovascular events (OR 1.8; 95% CI 1.07 – 3.34); and premature deaths (see table) by the 5th year of follow up (OR 2.9; 1.27- 6.55).
In a retrospective cohort, time duration 4 years or more from TA symptoms onset to diagnosis verification was associated with higher risk of cardiovascular events and lower survival rate.
[1]Mirouse C. et al. Ann. Rheum. Dis. 2018; 77(2): 10-48
[2]Dejaco C. et al. Ann. Rheum. Dis. 2018;77: 636-643
[3]Arend W.P. et al. Arthritis Rheum. 1990; 3(8): 1129-1134.
Artem Popov Speakers bureau: Novartis, Menarini, AstraZeneca, Pfizer, Severnaya Zvezda, Romepharm, Irina Borodina: None declared, Lubov Shardina: None declared |
|---|---|
| AbstractList | Takayasu arteritis (TA) is large vessel vasculitis. In spite of relatively high 5 to 15 years survival rate, TA affects young persons and causes major cardiovascular events, disability and preterm deaths [1]. Nowadays, though new high-resolution visualization and effective treatment options are available, quite a large number of TA patients remain undiagnosed and untreated for years [2].
To assess the influence of timely TA diagnosis and treatment initiation on the survival rate and cardiovascular events risk.
A retrospective cohort study included 183 patients (139 females, 44 males), enrolled during the period from 1979 to 2018 after TA diagnosis verification according to ACR1990 criteria [3]. All subjects have been followed up at the Sverdlovsk Regional Clinical Hospital 1. Cox regression model was used to compare survival rate.
By enrollment, females median age was 35 [25%-75%: 24 - 44] and in males median age was 34 [26 -42]. Median time duration from the first symptoms onset to the diagnosis verification was 3 [1-7] years in females and [1.5 - 8] years in males. The most common affected arteries were subclavian (55%), carotid (53%), and renal (42%). 5-year survival rate was 92%; 10-year survival rate was 90%; 15-year survival rate was 80%. The median term of survival was 34 [20 - 41] years. 31 deaths (18 males and 13 females) occurred during the follow-up period. Median age of death was 36 [32-44] in females, and 50 [40-57]) in males. The average disease course duration at the time of death was 9.25 years, median term being 6.5 [3-16] in females and 5 [3-10] in males. Also a total of 72 cardiovascular events were recorded during the follow-up period: 27 in men and 45 in women. The median duration of AT course by the development of the first ever event was 10 (5 -20). There were 24 cases of ischemic stroke, 3 transient ischemic attacks, 4 cases of hemorrhagic stroke. Median age of the first ever event was 38 (30 - 49.5). Time duration 4 years or more from AT symptoms onset to diagnosis was associated with significantly more frequent cardiovascular events (OR 1.8; 95% CI 1.07 – 3.34); and premature deaths (see table) by the 5th year of follow up (OR 2.9; 1.27- 6.55).
In a retrospective cohort, time duration 4 years or more from TA symptoms onset to diagnosis verification was associated with higher risk of cardiovascular events and lower survival rate.
[1]Mirouse C. et al. Ann. Rheum. Dis. 2018; 77(2): 10-48
[2]Dejaco C. et al. Ann. Rheum. Dis. 2018;77: 636-643
[3]Arend W.P. et al. Arthritis Rheum. 1990; 3(8): 1129-1134.
Artem Popov Speakers bureau: Novartis, Menarini, AstraZeneca, Pfizer, Severnaya Zvezda, Romepharm, Irina Borodina: None declared, Lubov Shardina: None declared |
| Author | Borodina, I. Popov, A. Shardina, L. |
| Author_xml | – sequence: 1 givenname: A. surname: Popov fullname: Popov, A. organization: Ural State Medical University, Hospital Therapy and Urgent Medical Care Service, Ekaterinburg, Russian Federation – sequence: 2 givenname: I. surname: Borodina fullname: Borodina, I. organization: Sverdlovsk Regional Clinical Hospital 1, Therapy, Yekaterinburg, Russian Federation – sequence: 3 givenname: L. surname: Shardina fullname: Shardina, L. organization: Ural State Medical University, Higher Medical Nurse and Social Education, Yekaterinburg, Russian Federation |
| BookMark | eNqNkEFPwjAAhXvARED_QxPPw3adWxdPDUxtBEa2QuKpKW0Xa2Az3TDx5sU_6i8RxIPxxOnlHd6XvG8AenVTWwCuMBphTOJrVdf-2e62xrVBiEIc2N1G-RFJ46gH-gghEkRpnJyDQdu-7CuimPbBLF8glKCvj898XmYCihxOOLuf5yUvoeCzDC6KbMLHooTlsljxFZvCgokM8jkU7JE9sXIJWSGyggteXoCzSm1ae_mbQ7C8y8T4IZjm93zMpoHGSRgFUWWqWJtYYxqG6zDG1K5JalNstKUYmUpRrDFWCqeGhBVBVCc3WtOYRkkUE0uG4PbI1b5pW28r-erdVvl3iZE82JB_bMiDDfljQx5s7Nfs31q7TnWuqTuv3OZERnZk2P3NN2e9bLWztbbGeas7aRp3Eucbh1GHEw |
| CitedBy_id | crossref_primary_10_1016_j_cjca_2025_03_022 crossref_primary_10_1016_j_cjca_2025_05_006 |
| ContentType | Journal Article |
| Copyright | 2021 © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by Elsevier Inc. |
| Copyright_xml | – notice: 2021 © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by Elsevier Inc. |
| DBID | AAYXX CITATION |
| DOI | 10.1136/annrheumdis-2021-eular.3964 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EndPage | 38 |
| ExternalDocumentID | 10_1136_annrheumdis_2021_eular_3964 S0003496724501765 |
| GroupedDBID | --- .55 .GJ .VT 0R~ 169 23M 2WC 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AALRI AAOJX AAWJN AAWTL AAXUO ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOAB ACOFX ACPRK ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DWQXO E3Z EBS EJD F5P FDB FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HYE HZ~ IAO IEA IHR INH INR IOF ITC J5H K9- KQ8 L7B LK8 M0R M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W2D W8F WH7 WOQ X6Y X7M YFH YOC YQY ZGI ZXP AAFWJ AAYXX ACQSR AFFHD AGQPQ CITATION PHGZM PJZUB PPXIY PQGLB |
| ID | FETCH-LOGICAL-c1724-4fdf6cd6c1822b2618eb39e91dce810dfa81c11aa19d32f308c75cc86847463e3 |
| ISSN | 0003-4967 |
| IngestDate | Sat Nov 29 08:15:01 EST 2025 Tue Nov 18 20:47:43 EST 2025 Sat Mar 15 15:41:46 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c1724-4fdf6cd6c1822b2618eb39e91dce810dfa81c11aa19d32f308c75cc86847463e3 |
| PageCount | 2 |
| ParticipantIDs | crossref_primary_10_1136_annrheumdis_2021_eular_3964 crossref_citationtrail_10_1136_annrheumdis_2021_eular_3964 elsevier_sciencedirect_doi_10_1136_annrheumdis_2021_eular_3964 |
| PublicationCentury | 2000 |
| PublicationDate | June 2021 2021-06-00 |
| PublicationDateYYYYMMDD | 2021-06-01 |
| PublicationDate_xml | – month: 06 year: 2021 text: June 2021 |
| PublicationDecade | 2020 |
| PublicationTitle | Annals of the rheumatic diseases |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| SSID | ssj0000818 |
| Score | 2.3551474 |
| Snippet | Takayasu arteritis (TA) is large vessel vasculitis. In spite of relatively high 5 to 15 years survival rate, TA affects young persons and causes major... |
| SourceID | crossref elsevier |
| SourceType | Enrichment Source Index Database Publisher |
| StartPage | 37 |
| Title | OP0070 ONSET TO DIAGNOSIS TIME PREDICTS SURVIVAL RATE IN TAKAYASU ARTERITIS |
| URI | https://dx.doi.org/10.1136/annrheumdis-2021-eular.3964 |
| Volume | 80 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database issn: 0003-4967 databaseCode: M7P dateStart: 19390101 customDbUrl: isFulltext: true dateEnd: 20241231 titleUrlDefault: http://search.proquest.com/biologicalscijournals omitProxy: false ssIdentifier: ssj0000818 providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database issn: 0003-4967 databaseCode: M0R dateStart: 19390101 customDbUrl: isFulltext: true dateEnd: 20241231 titleUrlDefault: https://search.proquest.com/familyhealth omitProxy: false ssIdentifier: ssj0000818 providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection issn: 0003-4967 databaseCode: 7X7 dateStart: 19390101 customDbUrl: isFulltext: true dateEnd: 20241231 titleUrlDefault: https://search.proquest.com/healthcomplete omitProxy: false ssIdentifier: ssj0000818 providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central issn: 0003-4967 databaseCode: BENPR dateStart: 19390101 customDbUrl: isFulltext: true dateEnd: 20241231 titleUrlDefault: https://www.proquest.com/central omitProxy: false ssIdentifier: ssj0000818 providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database issn: 0003-4967 databaseCode: M2P dateStart: 19390101 customDbUrl: isFulltext: true dateEnd: 20241231 titleUrlDefault: https://search.proquest.com/sciencejournals omitProxy: false ssIdentifier: ssj0000818 providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6FgiouiKdoeWgluFkOtndt73JAstoAFo0d1W5VTsZe26JS5UR9RD1y4Y_yS5h92IkoQkGIixWt4nU88-3nGWf2G4Reh6VPK1Ey2wk9YQNLcrsSsB4JMCFxG3gGVUoy_yBMEnZywmej0Zd-L8zyLOw6dn3NF__V1TAGzpZbZ__C3cOkMACfwelwBLfDcSPHpzMprmOKGJifJtkkt_LU2o-jD0maxZmVx9OJNP1-vJdnVnZ0eBwfy0KJKJcN6K08-hR9Brq1VKwb53G2HsGuFJdVceLX5kqLvpp_eoYQfTZfzJeKecZDyj8Htj7Vm9DiYVRKRvejB-P1txDeWrWUfjV2Y3uMoVtiU677bfR0qxs3Gb7Ugi_myatlXm5yOjFixuqW4G5s9QMaWaY7JlyLoP8imp1p4Z0g9KgPnBP4t9BtL_S55L2pc7h6VjOX9T0V5de30StzyTd_uODvY5i1uCS_j-6ZhAJHGggP0KjpHqLtqSmZeISmGg8_vn1XSMB5igckYIkE3CMB90jAEgk4TnCPBDwg4TE6ej_J9z7apoeGLSA0pTZt6zYQdSAgj_QqSJdZUxHecLcWsBCdui2ZK1y3LF1eE68lDhOhLwQLYK3SgDTkCdrq5l3zFGGPthANlqwU3KElLcsqqD1e1RAjQtJeBzvobW-VQhiBednn5KxQiSZRm997kxbSpIUyaSFNuoPocPJC66xsdtq73vyFCRl1KFgAejaZYPdfJ3iG7q7Ww3O0dXl-1bxAd8Ty8vTi_KVC208DBYx4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=OP0070%E2%80%85ONSET+TO+DIAGNOSIS+TIME+PREDICTS+SURVIVAL+RATE+IN+TAKAYASU+ARTERITIS&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Popov%2C+A.&rft.au=Borodina%2C+I.&rft.au=Shardina%2C+L.&rft.date=2021-06-01&rft.pub=Elsevier+B.V&rft.issn=0003-4967&rft.volume=80&rft.spage=37&rft.epage=38&rft_id=info:doi/10.1136%2Fannrheumdis-2021-eular.3964&rft.externalDocID=S0003496724501765 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |